Remove companies chinook-therapeutics-inc
article thumbnail

Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG

Benzinga

Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 The transaction has been unanimously approved by the Boards of Directors of both companies. "We

Equity 40
article thumbnail

Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement

Benzinga

31, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. 31, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. Upon completion of the merger, the combined company plans to operate under the name Jade Biosciences and trade on Nasdaq under the ticker symbol "JBIO."